Volume 35, No 1, Jan 2025

ISSN: 1001-0602 
EISSN: 1748-7838  
2020 impact factor 25.617*  
(Clarivate Analytics, 2021)

About the cover

The dual effects of glucocorticoids (GCs) are illustrated by bees. Left, low levels of GCs bind to the canonical high-affinity GC receptor (GR, the flower producing honey), mediating physiological and therapeutic effects. Right, high levels of GCs can also bind to the low-affinity receptor, tau, leading to bone loss and demonstrating pathological effects. See page 23–44 by Wenyu Fu et al. for details.

Advanced Online Publication: 9 Jan 2025

LETTERS TO THE EDITOR

Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis

Read more

Current Issue: Vol.35 (Jan 2025)

RESEARCH HIGHLIGHTS

Tau(t)ing glucocorticoid binding
Deciphering the role of immune system in the obesity–cancer relationship
LKB1 inactivation unleashes prostate cancer lineage plasticity
Immunity hubs orchestrating antiviral defense
NLRC5 PANoptosome: Aquaman of the Dead Sea

REVIEW ARTICLE

Modern biology of extrachromosomal DNA: A decade-long voyage of discovery

ORIGINAL ARTICLES

Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Reducing functionally defective old HSCs alleviates aging-related phenotypes in old recipient mice
LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer

LETTERS TO THE EDITOR

α-Synuclein amyloid fibril directly binds to LC3B and suppresses SQSTM1/p62-mediated selective autophagy
Structural insight into GPR55 ligand recognition and G-protein coupling
Structure basis of ligand recognition and activation of GPR55

CORRIGENDA

Correction: Sanofi-Cell Research outstanding paper award of 2023